US equities
|
NVDA
$237.21
▲+1.39%
MU
$1,059.00
▼-1.48%
SPCX
$164.74
▲+3.63%
TSLA
$375.50
▲+1.32%
MSFT
$527.46
▲+1.92%
INTC
$116.06
▼-2.74%
SNDK
$1,718.00
▼-0.12%
AMD
$627.67
▼-0.98%
NVDA
$237.21
▲+1.39%
MU
$1,059.00
▼-1.48%
SPCX
$164.74
▲+3.63%
TSLA
$375.50
▲+1.32%
MSFT
$527.46
▲+1.92%
INTC
$116.06
▼-2.74%
SNDK
$1,718.00
▼-0.12%
AMD
$627.67
▼-0.98%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
3.000
+0.120 (+4.17%)
Delayed Quote
Updated: 10:00 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD
September 24, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery
September 24, 2021
Via
Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Solution for Faster and More Effective Drug Delivery
September 24, 2021
Via
CannabisNewsWire
BTV Highlights Promising Investment Opportunities
September 23, 2021
Vancouver, British Columbia--(Newsfile Corp. - September 23, 2021) - On Sat. Sept 25th at 5pm EST broadcast on FOX Business...
Via
Newsfile
Topics
Artificial Intelligence
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enables Rapid, Sustained Drop in Blood Pressure
September 17, 2021
Via
Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enables Rapid, Sustained Drop in Blood Pressure
September 17, 2021
Via
CannabisNewsWire
Lexaria Takes Another Step Towards NDA Filing for DehydraTECH- CBD
September 14, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Lexaria to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021
KELOWNA, BC / ACCESSWIRE / September 9, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces today that...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins IND-Enabling Program for DehydraTECH-CBD for Hypertension
September 08, 2021
Via
CannabisNewsWire
Lexaria Starts IND-Enabling Program For DehydraTECH-CBD For Hypertension
↗
September 08, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) has formally begun the process towards an Investigational New Drug (IND) application filing with the FDA for its DehydraTECH...
Via
Benzinga
Lexaria Begins Investigational New Drug (IND) Enabling Program for DehydraTECH-CBD for Hypertension
September 08, 2021
Positive results using DehydraTECH-CBD support progressing to FDA IND application KELOWNA, BC / ACCESSWIRE / September 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
BTV News Alert Video: Lexaria Bioscience - The Way to Improve Drugs
September 07, 2021
Vancouver, British Columbia--(Newsfile Corp. - September 7, 2021) - Lexaria Bioscience (NASDAQ: LEXX) - Lexaria Bioscience began developing DehydraTECH in...
Via
Newsfile
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction
↗
September 07, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented...
Via
Benzinga
Why Lexaria Bioscience Shares Are Trading Higher Today
↗
September 07, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
September 07, 2021
Gainers Pliant Therapeutics (NASDAQ:PLRX) shares rose 25.62% to $24.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $872.2...
Via
Benzinga
Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients
↗
September 07, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced initial results from human clinical study HYPER-H21-2 evaluating DehydraTECH-processed cannabidiol (CBD) for potential...
Via
Benzinga
Lexaria's Human Clinical Study Delivers Effective and Safe Blood Pressure Reduction Results over 24-hour Ambulatory Period
September 07, 2021
Human Clinical Study HYPER-H21-2 evidences up to a remarkable 23% decrease in blood pressure with patented DehydraTECH-CBD relative to placebo KELOWNA, BC / ACCESSWIRE / September 7, 2021 / Lexaria...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Proprietary Technology Elevating Quantity of Drugs Delivered Across Blood-Brain Barrier by 1,900%
September 03, 2021
Via
CannabisNewsWire
Topics
Animal Testing
Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Targets Burgeoning Hypertension, Antiviral Therapeutics Markets With Drug Delivery Technology
↗
September 02, 2021
Lexaria has progressed significantly in evidencing that its patented DehydraTECH(TM) drug delivery technology can sufficiently improve the usable fraction of known antiviral...
Via
Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology Is ‘Outrageously Fast’ in Oral to Bloodstream Delivery
August 27, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in PCG Report Noting Company Could Deliver for Investors
August 17, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH Provides Potential for Significant Cost Savings to Health Care System
August 13, 2021
Via
CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Well Positioned to Advance Business, Further Execute on Drug-Delivery Goals
August 06, 2021
Via
CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Hails Successful Testing for Effective Transformation of Antivirals for Greater Bioavailability
July 29, 2021
Via
CannabisNewsWire
Lexaria's R&D Program Reveals 5 Exciting Results Within 2 Months
↗
July 29, 2021
Image by Lucas Vasques on Unsplash Biotech company Lexaria Bioscience Corp. (NASDAQ: LEXX) has been making news for DehydraTECH™ — its proprietary disruptive and cost-...
Via
Benzinga
Lexaria's DehydraTECH-CBD Lowers Blood Pressure
July 29, 2021
Human Clinical Study HYPER-H21-1 evidences a rapid and sustained drop in blood pressure with DehydraTECH-CBD and excellent tolerability KELOWNA, BC / ACCESSWIRE / July 29, 2021 / Lexaria Bioscience...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products
July 28, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
DehydraTECH-Enabled Consumer Products Now Available in Over 7,000 Stores
July 28, 2021
Lexaria's technology empowers brands nationwide in stores including Albertsons, Hudson News, and many more KELOWNA, BC / ACCESSWIRE / July 28, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Supply Chain
Lexaria Bioscience Corp. (NASDAQ: LEXX) Completes VIRAL-A20-3 Pharmacokinetic Study on DehydraTECH(TM) Enabled Colchicine
July 27, 2021
Via
CannabisNewsWire
Topics
Intellectual Property
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
July 27, 2021
Gainers Eyegate Pharmaceuticals (NASDAQ:EYEG) shares increased by 131.41% to $7.22 during Tuesday's pre-market session. The company's market cap stands at $51.2...
Via
Benzinga
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
